Dr. McGarrity asked Mr. Lanman if such wording would have 
prevented the Argentine occurrence from happening. Mr. Lanman 
said he had not reviewed the situation recently, but he believed 
that it would have prevented the incident. Mr. Lanman noted that 
no mention of compliance with USDA rules was made in any version 
of the NIH Guidelines. Dr. Shibley said he felt the language 
should be clearer. In his opinion in the case of the Wistar 
experiment, the Wistar IBC could have approved the export of the 
vaccine to Argentina. Since Argentina had no IBC, the experiment 
would have taken place anyway. 
Dr. Riley said she believed the IBC or equivalent body referred 
to in the proposed amendment was one located in the foreign 
country. Dr. Childress replied he did not believe it was limited 
to the foreign country but merely an IBC which met NIH standards. 
Dr. Cohen said he agreed with Dr. Childress' interpretation. 
Dr. Atlas said in the case of a Wistar IBC approving the 
experiment, it would still require "acceptance in writing by an 
appropriate national governmental authority," that was missing in 
the Wistar scenario. Dr. Shibley said it was not clear whether 
"national governmental authority" referred to a foreign 
government or a domestic governmental authority. If the latter 
were true, Wistar 's IBC could approve the experiment, USDA could 
approve export, and the Argentinean government would still be 
unaware of the experiment. 
Dr. Davis suggested adding the words "of the host country" after 
the word "authority" in the final paragraph for clarification. 
Dr. Atlas moved adoption of the proposed amendment of Section I-C 
of the NIH Guidelines with the addition of the phrase "of the 
host country" after the word "authority" in the final paragraph. 
Dr. Cohen seconded the motion. 
Dr. McGarrity asked if there was discussion on the motion. 
Dr. Warren Cheston of the Wistar Institute said the Institute 
would support these NIH Guidelines enthusiastically. 
There being no further discussion. Dr. McGarrity put the motion 
to a vote. The motion passed unanimously with 20 in favor 0 
opposed, and no abstentions. Dr. McGarrity then called on 
Dr. Vidaver to present the next agenda item. 
V. PROPOSED AMENDMENT OF SECTION I-B (TABS 1332/III, 1339, 1342): 
Dr. Vidaver proposed the following suggested statement be added 
to Section I-B of the NIH Guidelines: 
Recombinant DNA Research, Volume 13 
[257] 
